XML 39 R24.htm IDEA: XBRL DOCUMENT v3.20.2
The Business and Summary of Significant Accounting Policies - Revenue Recognition (Details)
3 Months Ended 9 Months Ended 12 Months Ended 116 Months Ended 121 Months Ended
Sep. 30, 2020
USD ($)
Sep. 30, 2019
USD ($)
Sep. 30, 2020
USD ($)
Sep. 30, 2019
USD ($)
Sep. 30, 2020
USD ($)
Sep. 30, 2020
USD ($)
Feb. 15, 2021
USD ($)
revenue_contract
base_segment
option_segment
Oct. 31, 2019
USD ($)
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                
Total revenues $ 1,609,000 $ 1,958,000 $ 4,252,000 $ 5,752,000        
BARDA                
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                
Total revenues 1,600,000 2,000,000.0 4,200,000 5,800,000   $ 74,400,000    
BARDA | Scenario, Forecast                
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                
Total revenues             $ 78,900,000  
Total number of base segments | base_segment             1  
Total number of option segments | option_segment             4  
Total number of separate contracts | revenue_contract             5  
BARDA | Expense reimbursement | Scenario, Forecast                
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                
Total revenues             $ 75,800,000  
BARDA | Fees | Scenario, Forecast                
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                
Total revenues             5,300,000  
BARDA Fourth Option Segment | Scenario, Forecast                
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                
Total revenues             $ 4,600,000  
SymBio Pharmaceuticals                
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                
Total revenues         $ 5,000,000.0      
Initial upfront payment to be received   5,000,000.0   5,000,000.0       $ 5,000,000.0
Payment to be received upon achievement of milestones $ 180,000,000.0 $ 180,000,000 $ 180,000,000.0 $ 180,000,000 $ 180,000,000.0 $ 180,000,000.0